Monoclonal antibody | |
---|---|
Type | ? |
Source | Human |
Target | BAFF receptor |
Clinical data | |
Other names | VAY736 |
ATC code |
|
Identifiers | |
CAS Number | |
UNII | |
KEGG |
Ianalumab ( INN; [1] development code VAY736) is a monoclonal antibody that is being investigated for autoimmune hepatitis, multiple sclerosis, pemphigus vulgaris, rheumatoid arthritis, Sjögren syndrome, and systemic lupus erythematosus. [2] [3] [4]
This drug is being developed by Novartis. In 2021 ianalumab was undergoing Phase II/ III trials. [5] [6] In June 2023 ianalumab was involved in 22 clinical trials, of which 3 were completed, 14 were ongoing, 1 was planned, and 4 were terminated. [7]
Monoclonal antibody | |
---|---|
Type | ? |
Source | Human |
Target | BAFF receptor |
Clinical data | |
Other names | VAY736 |
ATC code |
|
Identifiers | |
CAS Number | |
UNII | |
KEGG |
Ianalumab ( INN; [1] development code VAY736) is a monoclonal antibody that is being investigated for autoimmune hepatitis, multiple sclerosis, pemphigus vulgaris, rheumatoid arthritis, Sjögren syndrome, and systemic lupus erythematosus. [2] [3] [4]
This drug is being developed by Novartis. In 2021 ianalumab was undergoing Phase II/ III trials. [5] [6] In June 2023 ianalumab was involved in 22 clinical trials, of which 3 were completed, 14 were ongoing, 1 was planned, and 4 were terminated. [7]